On Thursday, Shares of Delta Air Lines, Inc. (NYSE:DAL), gained 0.32% to $43.84.
Delta Air Lines, will launch alliances with nine universities across the country that go beyond traditional stadium signage to embed the airline and its employees in campus and alumni events, academics and career recruiting and counseling, all in an effort to become a lifelong travel partner to future customers.
By employing a team of college seniors, Delta has gained direct insight into the needs of its next generation of customers. Students’ feedback following an eight-week intensive internship at the airline’s Atlanta headquarters formed the foundation for Delta’s groundbreaking approach to university partnerships.
“College students are a savvy group of consumers,” said Jeff Robertson, Delta Vice President – Product Development, Sky Clubs and Marketing Communications. “By creating campus and alumni events that incorporate our people, our unmatched focus on customer service, leadership and more, we will give students and alums the opportunity to really get to know our airline. Ultimately, we believe this will position Delta as their trusted partner over a lifetime of travel.”
Delta Air Lines, Inc. provides planned air transportation for passengers and cargo worldwide. The company operates in two segments, Airline and Refinery. Its route network comprises various gateway airports in Amsterdam, Detroit, Los Angeles, Minneapolis-St. Paul, New York-LaGuardia, New York-JFK, Paris-Charles de Gaulle, Salt Lake City, Seattle, and Tokyo-Narita.
Shares of Cobalt International Energy, Inc. (NYSE:CIE), inclined 5.81% to $8.38, during its last trading session.
Cobalt International Energy, declared a net loss of $66.8 million, or $0.16 per basic and diluted share for the second quarter of 2015, contrast to a net loss of $94.8 million, or $0.23 per basic and diluted share, for the second quarter of 2014. The current quarter comprised of $4.4 million of impairment charges for the formerly declared abandonment of the North Platte #2 appraisal well.
Capital and operating expenditures (not taking into account changes in working capital) for the quarter ending June 30, 2015 was about $205 million, in line with Cobalt’s planned capital and operating expenditures of about $800-900 million in 2015. Cash, cash equivalents, investments, and undrawn amounts under the Heidelberg Facility Agreement at the end of the second quarter were about $1.9 billion. This comprises about $82 million held for future operations in collateralizing letters of credit.
Cobalt International Energy, Inc., through its auxiliaries, engages in the exploration and production of oil-focused, below-salt exploration prospects. Its project portfolio comprises North Platte, Heidelberg, Shenandoah, and Anchor discovery in the U.S. Gulf of Mexico; Cameia, Lontra, Mavinga, Bicuar, and Orca in the offshore Angola; and Diaman in the offshore Gabon.
Finally, Transgenomic Inc (NASDAQ:TBIO), ended its last trade with 7.14% gain, and closed at $1.20.
Transgenomic, declared the addition of distributors in China and Japan for its ICEme™ Mutation Enrichment Kits for genomics research. The recently-launched kits use Transgenomic’s Multiplexed ICE COLD-PCR™ (MX-ICP) technology and are designed to facilitate genomics-based cancer research. The new distributors comprise Spectron Scientific Co., Ltd. in China and Sowa Trading Co., Inc., in Japan, who are established suppliers of advanced life science products to researchers at universities, pharmaceutical and biotech companies, and research institutes in their respective markets.
“Asia represents important and growing markets for cancer research, and our ICEme Kits will allow researchers in China and Japan to use the sequencing platforms already in their labs to conduct sophisticated genetic analyses to accelerate their cancer research and drug discovery programs,” commented Paul Kinnon, President, and Chief Executive Officer of Transgenomic. “We expect to declare additional distributors in other key territories soon.”
Transgenomic, Inc., a biotechnology company, engages in advancing personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and clinical and research services in the United States and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
